Table 3.
Moderation of physical activity on the relationship between amyloid positivity and AD-related neurodegeneration
| PA period | Dependent variable | Independent variable | Beta | 95% CI | p |
|---|---|---|---|---|---|
| Midlife | AD-CM | PA | 0.069 | 0.000~0.000 | 0.358 |
| Aβ positivity | −0.174 | −0.107~0.005 | 0.072 | ||
| PA × Aβ positivity | −0.058 | 0.000~0.000 | 0.553 | ||
| AD-CT | PA | −0.041 | 0.000~0.000 | 0.532 | |
| Aβ positivity | −0.212 | −0.145~−0.019 | 0.011 | ||
| PA × Aβ positivity | 0.094 | 0.000~0.001 | 0.267 | ||
| Late-life | AD-CM | PA | −0.013 | 0.000~0.000 | 0.852 |
| Aβ positivity | −0.319 | −0.144~−0.043 | <0.001 | ||
| PA × Aβ positivity | 0.162 | 0.000~0.001 | 0.060 | ||
| AD-CT | PA | −0.013 | 0.000~0.000 | 0.833 | |
| Aβ positivity | −0.289 | −0.169~−0.056 | < 0.001 | ||
| PA × Aβ positivity | 0.214 | 0.000~0.001 | 0.004 |
Adjusted for age, sex, education, apolipoprotein E ε4, vascular risk score, cognitive activity score, and clinical diagnosis. AD, Alzheimer’s disease; PA, physical activity; CI, confidence interval; AD-CM, Alzheimer’s disease signature region cerebral glucose metabolism; Aβ, amyloid-β; AD-CT, Alzheimer’s disease signature cortical thickness.